Intestinal lymphatic drug transport: an update

被引:258
作者
Porter, CJH [1 ]
Charman, WN [1 ]
机构
[1] Monash Univ, Victorian Coll Pharm, Dept Pharmaceut, Parkville, Vic 3052, Australia
关键词
lymphatic transport; lipids; drug absorption; lipidic formulations; bioavailability;
D O I
10.1016/S0169-409X(01)00151-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The trend towards identification of poorly water-soluble and highly Lipophilic candidate drug molecules has led to an increase in interest in intestinal lymphatic drug transport. In this article we provide a brief background to the mechanism of access of drugs to the intestinal lymph and the role of lipid digestion and absorption in the stimulation of lymphatic transport. The ability of different lipid types to stimulate lymphatic drug transport, is addressed, concentrating specifically on the impact of the class, chain length and degree of unsaturation of co-administered lipids. Comment is also made as to the relevance of dosing different lipid volumes to the rat and the possible complications this may provide when trying to assess the likely extent of intestinal lymphatic transport. Recent studies are described in which the extent of lymphatic transport of a highly lipophilic antimalarial, halofantrine, was investigated after post-prandial administration to greyhound dogs. Finally the possible future directions for studies of intestinal lymphatic transport are discussed, including the use of cell culture models and genetically modified animals. (C) 2001 Elsevier Science BY All rights reserved.
引用
收藏
页码:61 / 80
页数:20
相关论文
共 149 条
[1]   Intestinal fatty acid binding protein may favor differential apical fatty acid binding in the intestine [J].
Alpers, DH ;
Bass, NM ;
Engle, MJ ;
DeSchryver-Kecskemeti, K .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2000, 1483 (03) :352-362
[2]   Predicting human oral bioavailability of a compound: Development of a novel quantitative structure-bioavailability relationship [J].
Andrews, CW ;
Bennett, L ;
Yu, LX .
PHARMACEUTICAL RESEARCH, 2000, 17 (06) :639-644
[3]  
Aungst BJ, 2000, J PHARM SCI, V89, P429, DOI 10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO
[4]  
2-J
[5]   MEDIUM-CHAIN TRIGLYCERIDES - AN UPDATE [J].
BACH, AC ;
BABAYAN, VK .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 1982, 36 (05) :950-962
[6]   MDR1 gene expression in normal and atherosclerotic human arteries [J].
Batetta, B ;
Dessi, S ;
Putzolu, M ;
Sanna, F ;
Spano, O ;
Mulas, MF ;
Petruzzo, P ;
Cappai, A ;
Brotzu, G .
JOURNAL OF VASCULAR RESEARCH, 1999, 36 (04) :261-271
[7]   Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery [J].
Benet, LZ ;
Izumi, T ;
Zhang, YC ;
Silverman, JA ;
Wacher, VJ .
JOURNAL OF CONTROLLED RELEASE, 1999, 62 (1-2) :25-31
[8]   A COMPARISON OF ABSORPTION OF GLYCEROL TRISTEARATE AND GLYCEROL TRIOLEATE BY RAT SMALL-INTESTINE [J].
BERGSTEDT, SE ;
HAYASHI, H ;
KRITCHEVSKY, D ;
TSO, P .
AMERICAN JOURNAL OF PHYSIOLOGY, 1990, 259 (03) :G386-G393
[9]   DIFFERENTIAL INTESTINAL-ABSORPTION OF 2 FATTY-ACID ISOMERS - ELAIDIC AND OLEIC ACIDS [J].
BERNARD, A ;
ECHINARD, B ;
CARLIER, H .
AMERICAN JOURNAL OF PHYSIOLOGY, 1987, 253 (06) :G751-G759
[10]   INTESTINAL LYMPH AS PATHWAY FOR TRANSPORT OF ABSORBED FATTY ACIDS OF DIFFERENT CHAIN LENGTHS [J].
BLOOM, B ;
CHAIKOFF, IL ;
REINHARDT, WO .
AMERICAN JOURNAL OF PHYSIOLOGY, 1951, 166 (02) :451-455